HER2-positive Carcinoma of Breast Active Not Recruiting Phase 3 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0070633 (HER2-positive Carcinoma of Breast)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02162667Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast CancerTreatment